Summary Faron Pharmaceuticals Oy (Faron) is a clinical stage biopharmaceutical company that conducts clinical stage drug discovery and development.The company’s pipeline products focus on cute organ traumas, vascular damage and cancer immunotherapy.
It offers Traumakine, that helps to prevent vascular leakage and organ failures and is the only treatment for acute respiratory distress syndrome (ARDS).Faron’s Clevegen is a pre-clinical anti-Clever-1 antibody that has the ability to switch immune suppression to immune activation in various conditions.
The company’s Clevegen can be used for oncology, infectious disease and vaccine development.It partners with academic institutions and pharmaceutical companies.
Faron is headquartered in Turku, Finland.
Faron Pharmaceuticals Oy (FARN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
Aplastic Anemia - Pipeline Review, H2 2019 Summary The latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia - Pipeline Review, H2 2019, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape. Aplastic anemia is a syndrome of bone marrow...
Interleukin 1 - Pipeline Review, H1 2020 Summary Interleukin 1 (IL1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Interleukin 1 (IL1) - Pipeline Review, H1 2020,...
Phenylalanine 4 Hydroxylase - Pipeline Review, H2 2019 Summary Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 22.214.171.124) - Phenylalanine 4 hydroxylase or Phenylalanine hydroxylase (PAH) is an enzyme that catalyzes the hydroxylation of the aromatic side-chain of phenylalanine to generate...
Hepatocyte Growth Factor - Pipeline Review, H2 2019 Summary Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 13 molecules. The latest report Hepatocyte Growth Factor - Pipeline Review, H2 2019, outlays comprehensive information on the Hepatocyte...
Alpha Galactosidase A - Pipeline Review, H2 2019 Summary Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 126.96.36.199) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed...
Alpha L-Iduronidase - Pipeline Review, H2 2019 Summary Alpha L-Iduronidase (IDUA or EC 188.8.131.52) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Alpha L-Iduronidase...
Lysosomal Alpha Glucosidase - Pipeline Review, H1 2020 Summary Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 184.108.40.206) - Lysosomal alpha-glucosidase is an enzyme encoded by the GAA gene. It is essential for the degradation of glygogen to glucose in lysosomes. Defects...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.